SCHEMBL5152852

SCHEMBL5152852

CC(C)(C)OC(=O)N1CCCC1CNc1ccc(C(=O)O)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.53
FPR3 P25089 1/20 0.49
FPR2 P25090 1/20 0.49
OPRD1 P41143 1/20 0.46
KDM1A O60341 1/20 0.45
LTA4H P09960 1/20 0.44
PRMT5 O14744 1/20 0.44
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
ABL1 P00519 1/20 0.42
RIN1 Q13671 1/20 0.42
KDM4E B2RXH2 1/20 0.42
PKM P14618 1/20 0.42
LMNA P02545 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
APP P05067 1/20 0.41
HTR1A P08908 1/20 0.41
ADRA2A P08913 1/20 0.41
DRD2 P14416 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5150103 0.90 NPC1 (0.52) NPC1FPR3FPR2OPRD1KDM1A
SCHEMBL12311356 0.90 OPRD1 (0.53) NPC1FPR3FPR2OPRD1KDM1A
SCHEMBL12810104 0.87 FPR2 (0.62) NPC1FPR3FPR2OPRD1KDM1A
SCHEMBL4308216 0.87 PRMT5 (0.50) NPC1FPR3FPR2OPRD1KDM1A
SCHEMBL29939753 0.87 NPC1 (0.48) NPC1FPR3FPR2OPRD1KDM1A
SCHEMBL4308226 0.87 PRMT5 (0.50) NPC1FPR3FPR2OPRD1KDM1A
SCHEMBL4313129 0.86 PRMT5 (0.49) NPC1FPR3FPR2OPRD1KDM1A
SCHEMBL4313122 0.86 PRMT5 (0.49) NPC1FPR3FPR2OPRD1KDM1A
SCHEMBL9074577 0.85 FPR3 (0.49) NPC1FPR3FPR2OPRD1KDM1A
SCHEMBL9074580 0.85 FPR3 (0.49) NPC1FPR3FPR2OPRD1KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070054909-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-03-08 US disclosed
US-7179819-B2 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-02-20 US disclosed
EP-1189612-A4 VLA-4 INHIBITOR COMPOUNDS DAIICHI SEIYAKU CO (JP) 2005-02-16 EP disclosed
US-20040229858-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-11-18 US disclosed
EP-1189612-A1 VLA-4 INHIBITOR COMPOUNDS Daiichi Pharmaceutical Co., Ltd. (JP) 2002-03-27 EP disclosed
WO-2001000206-A1 VLA-4 INHIBITOR COMPOUNDS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054909-A1 VLA-4 inhibitor compounds VCAM1, ITGB4, ICAM1 NPC1 3300/4885FPR3 303/4885FPR2 414/4885
US-20040229858-A1 VLA-4 inhibitor compounds VCAM1, ICAM1, ITGB4 NPC1 2981/4885FPR3 294/4885FPR2 405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.